Physician profile
Can Talug
NPI 1972708535
$1,156.31
in general payments reported to CMS, 2019-2025
18 companies · $43.83 in 2025
The $43.83 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.04 · 2021: $327 · 2022: $252 · 2023: $453 · 2024: $53.47 · 2025: $43.83.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $550.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| C. R. Bard, INC. & Subsidiaries | $291.97 | 2023-2025 | Bard Urinary Drainage Bag, Personal Catheter Intermittent Catheter |
| Astellas Pharma US INC | $172.86 | 2021-2023 | Xtandi |
| Janssen Biotech, INC. | $130.14 | 2022 | |
| Cook Medical LLC | $130.12 | 2019-2023 | Resonance |
| Pfizer INC. | $93.44 | 2022-2023 | |
| Myovant Sciences INC. | $59.44 | 2021 | |
| Boston Scientific Corporation | $47.78 | 2021-2023 | Lithovue |
| Alexion Pharmaceuticals, INC. | $35.45 | 2021-2022 | |
| Myriad Genetic Laboratories, INC. | $30.16 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $24.08 | 2023 | Andexxa |
| Axonics, INC. | $18.99 | 2023 | Axonics |
| Koelis INC. | $18.48 | 2023 | |
| Genzyme Corporation | $18.17 | 2021 | |
| Sumitomo Pharma America, INC. | $17.61 | 2023 | Gemtesa |
| Merck Sharp & Dohme LLC | $17.28 | 2023 | Lynparza, Keytruda |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Progenics Pharmaceuticals, INC. | $16.98 | 2023 | Pylarify |
| Allergan, INC. | $16.78 | 2021 | |
| Laborie Medical Technologies Corp. | $16.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Can Talug listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.